Transpiration and leaf growth of potato clones in response to soil water deficit

Potato (Solanum tuberosum ssp. Tuberosum) crop is particularly susceptible to water deficit because of its small and shallow root system. The fraction of transpirable soil water (FTSW) approach has been widely used in the evaluation of plant responses to water deficit in different crops. The FTSW 34 threshold (when stomatal closure starts) is a trait of particular interest because it is an indicator of tolerance to water deficit. The FTSW threshold for decline in transpiration and leaf growth was evaluated in a drying soil to identify potato clones tolerant to water deficit. Two greenhouse experiments were carried out in pots, with three advanced clones and the cultivar Asterix. The FTSW, transpiration and leaf growth were measured on a daily basis, during the period of soil drying. FTSW was an efficient method to separate potato clones with regard to their response to water deficit. The advancedclones SMINIA 02106-11 and SMINIA 00017-6 are more tolerant to soil water deficit than the cultivar Asterix, and the clone SMINIA 793101-3 is more tolerant only under high solar radiation

Galactic archaeology with asteroseismology and spectroscopy: Red giants observed by CoRoT and APOGEE

With the advent of the space missions CoRoT and Kepler, it has recently become feasible to determine precise asteroseismic masses and relative ages for large samples of red giant stars. We present the CoRoGEE dataset, obtained from CoRoT light curves for 606 red giants in two fields of the Galactic disc that have been co-observed by the Apache Point Observatory Galactic Evolution Experiment (APOGEE). We used the Bayesian parameter estimation code PARAM to calculate distances, extinctions, masses, and ages for these stars in a homogeneous analysis, resulting in relative statistical uncertainties of ≲2% in distance, ~4% in radius, ~9% in mass and ~25% in age. We also assessed systematic age uncertainties stemming from different input physics and mass loss. We discuss the correlation between ages and chemical abundance patterns of field stars over a broad radial range of the Milky Way disc (5 kpc <RGal< 14 kpc), focussing on the [α/Fe]-[Fe/H]-age plane in five radial bins of the Galactic disc. We find an overall agreement with the expectations of pure chemical-evolution models computed before the present data were available, especially for the outer regions. However, our data also indicate that a significant fraction of stars now observed near and beyond the solar neighbourhood migrated from inner regions. Mock CoRoGEE observations of a chemodynamical Milky Way disc model indicate that the number of high-metallicity stars in the outer disc is too high to be accounted for even by the strong radial mixing present in the model. The mock observations also show that the age distribution of the [α/Fe]-enhanced sequence in the CoRoGEE inner-disc field is much broader than expected from a combination of radial mixing and observational errors. We suggest that a thick-disc/bulge component that formed stars for more than 3 Gyr may account for these discrepancies. Our results are subject to future improvements due to (a) the still low statistics, because our sample had to be sliced into bins of Galactocentric distances and ages; (b) large uncertainties in proper motions (and therefore guiding radii); and (c) corrections to the asteroseismic mass-scaling relation. The situation will improve not only upon the upcoming Gaia data releases, but also with the foreseen increase in the number of stars with both seismic and spectroscopic information

Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: Results from the CREDENCE trial and meta-analysis

BACKGROUND AND PURPOSE: Chronic kidney disease with reduced estimated glomerular filtration rate or elevated albuminuria increases risk for ischemic and hemorrhagic stroke. This study assessed the effects of sodium glucose cotransporter 2 inhibitors (SGLT2i) on stroke and atrial fibrillation/flutter (AF/AFL) from CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation) and a meta-Analysis of large cardiovascular outcome trials (CVOTs) of SGLT2i in type 2 diabetes mellitus. METHODS: CREDENCE randomized 4401 participants with type 2 diabetes mellitus and chronic kidney disease to canagliflozin or placebo. Post hoc, we estimated effects on fatal or nonfatal stroke, stroke subtypes, and intermediate markers of stroke risk including AF/AFL. Stroke and AF/AFL data from 3 other completed large CVOTs and CREDENCE were pooled using random-effects meta-Analysis. RESULTS: In CREDENCE, 142 participants experienced a stroke during follow-up (10.9/1000 patient-years with canagliflozin, 14.2/1000 patient-years with placebo; hazard ratio [HR], 0.77 [95% CI, 0.55-1.08]). Effects by stroke subtypes were: ischemic (HR, 0.88 [95% CI, 0.61-1.28]; n=111), hemorrhagic (HR, 0.50 [95% CI, 0.19-1.32]; n=18), and undetermined (HR, 0.54 [95% CI, 0.20-1.46]; n=17). There was no clear effect on AF/AFL (HR, 0.76 [95% CI, 0.53-1.10]; n=115). The overall effects in the 4 CVOTs combined were: Total stroke (HRpooled, 0.96 [95% CI, 0.82-1.12]), ischemic stroke (HRpooled, 1.01 [95% CI, 0.89-1.14]), hemorrhagic stroke (HRpooled, 0.50 [95% CI, 0.30-0.83]), undetermined stroke (HRpooled, 0.86 [95% CI, 0.49-1.51]), and AF/AFL (HRpooled, 0.81 [95% CI, 0.71-0.93]). There was evidence that SGLT2i effects on total stroke varied by baseline estimated glomerular filtration rate (P=0.01), with protection in the lowest estimated glomerular filtration rate (45 mL/min/1.73 m2]) subgroup (HRpooled, 0.50 [95% CI, 0.31-0.79]). CONCLUSIONS: Although we found no clear effect of SGLT2i on total stroke in CREDENCE or across trials combined, there was some evidence of benefit in preventing hemorrhagic stroke and AF/AFL, as well as total stroke for those with lowest estimated glomerular filtration rate. Future research should focus on confirming these data and exploring potential mechanisms

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to 300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m 2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to &lt;90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], &gt;300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of &lt;15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P&lt;0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P&lt;0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

Comportamento ingestivo de cordeiras em pastagem consorciada de inverno sob diferentes intensidades de desfolha Ingestive behavior of lambs on mixed winter pasture under different grazing intensities

Avaliou-se a relação entre a estrutura do pasto, as variáveis ambientais e o comportamento ingestivo de cordeiras Ile de France × Texel em pastagem consorciada de aveia-preta (Avena strigosa Schreb.), azevém (Lolium multiflorum Lam.) e trevo-vermelho (Trifolium pratense L.) sob quatro intensidades de desfolha (muito alta, alta, média e baixa). Utilizaram-se pastejos intermitentes considerando a soma térmica de 300 graus-dia como critério para determinar os intervalos de pastejo. As avaliações do comportamento ingestivo foram feitas por meio de observação visual em quatro períodos contínuos de 24 horas realizados no período de maio a outubro de 2006. O maior tempo de pastejo ocorreu na intensidade baixa. Altas intensidades de desfolha ocasionaram aumento da densidade populacional de perfilhos de azevém e não alteraram o peso desses perfilhos. A massa de bocados e a qualidade da dieta selecionada pelas cordeiras foram semelhantes entre as intensidades testadas. Em pastagem de aveia+azevém+trevo-vermelho, quando o intervalo de pastejo é determinado pela soma térmica de 300 graus-dia, a utilização de intensidades de desfolha que variam de baixa a muito alta não altera o comportamento ingestivo de cordeiras. O comportamento ingestivo é afetado pelo ciclo do pasto e pelo fotoperíodo e a seletividade dos animais reduz ao final do período de utilização da pastagem, quando ocorre aumento no tempo de pastejo e na distância percorrida em busca de locais de alimentação.<br>The relationship between the pasture structure, environmental variables and the ingestive behavior of crossbred Ile de France-Texel lambs on a mixed winter pasture of oats (Avena strigosa Schreb.), Italian ryegrass (Lolium multiflorum Lam.), and red clover (Trifolium pratense L.) under four grazing intensities ('very high', 'high', 'average', and 'low') was evaluated. Intermittent grazing was used, considering the thermal sum of 300 degree-days to determine the grazing interval. The evaluations of ingestive behavior were made by visual observation, in four continuous periods of 24 hours, conducted from May to October 2006. The highest grazing time occurred in 'low' grazing intensity. The 'high' grazing intensity increased Italian ryegrass density of tillers, without altering the tiller weight. The grazing intensity did not affect the bite weight and the diet quality selected by the animals. Using oats+Italian ryegrass+red clover pasture with a grazing interval determined by the thermal sum of 300 degree-day, grazing intensities can vary from 'low' to 'very high' without modify the lamb ingestive behavior. Ingestive behavior variables is affected by the grazing cycle and photoperiod. At the end of the grazing cycle the selectivity of the grazing animals is reduced, increasing both the time dedicated to grazing and the distance covered on the search for food patches